Psychostimulant Treatment of Cocaine Dependence

Psychiatric Clinics of North America

Volumn 35, Issue 2, 2012, Pages 425-439

  Mariani, John J ^a,b   Levin, Frances R ^a,b  

^a NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^b College of Physicians and Surgeons of Columbia University ^*  (United States)

Author keywords

Amphetamines; Cocaine dependence; Dopamine; Methylphenidate; Psychostimulant; Substance abuse

Indexed keywords

AMFEBUTAMONE; AMPHETAMINE; ARMODAFINIL; CARBIDOPA PLUS LEVODOPA; COCAINE; DEXAMPHETAMINE; MAZINDOL; METHADONE; METHAMPHETAMINE; METHYLPHENIDATE; MODAFINIL; PLACEBO; PSYCHOSTIMULANT AGENT; SELEGILINE; VIGABATRIN;

ATTENTION DEFICIT DISORDER; COCAINE DEPENDENCE; COGNITIVE THERAPY; CONTROLLED CLINICAL TRIAL (TOPIC); DOPAMINE RELEASE; DOPAMINERGIC TRANSMISSION; DOSE RESPONSE; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG MECHANISM; HUMAN; NEUROBIOLOGY; NONHUMAN; OPIATE ADDICTION; PRESCRIPTION; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; REINFORCEMENT; REVIEW;

AMPHETAMINES; ANIMALS; BENZHYDRYL COMPOUNDS; BUPROPION; CENTRAL NERVOUS SYSTEM STIMULANTS; CLINICAL TRIALS AS TOPIC; COCAINE; COCAINE-RELATED DISORDERS; COMBINED MODALITY THERAPY; DOPAMINE AGENTS; HUMANS; METHYLPHENIDATE; PLACEBOS; RATS; REINFORCEMENT (PSYCHOLOGY); UNITED STATES;

EID: 84861468956     PISSN: 0193953X     EISSN: 15583147     Source Type: Journal    
DOI: 10.1016/j.psc.2012.03.012     Document Type: Review

References (66)

1. Results from the 2008 National Survey on Drug Use and Health: National Findings 2009, SAMHSA, Office of Applied Studies, Rockville (MD).
2. Compton W.M., Thomas Y.F., Stinson F.S., et al. Prevalence, correlates, disability, and comorbidity of DSM-IV drug abuse and dependence in the United States: results from the national epidemiologic survey on alcohol and related conditions. Arch Gen Psychiatry 2007, 64(5):566-576.
3. Dutra L., Stathopoulou G., Basden S.L., et al. A meta-analytic review of psychosocial interventions for substance use disorders. Am J Psychiatry 2008, 165(2):179-187.
4. de Lima M.S., de Oliveira Soares B.G., Reisser A.A., et al. Pharmacological treatment of cocaine dependence: a systematic review. Addiction 2002, 97(8):931-949.
5. Elkashef A., Holmes T.H., Bloch D.A., et al. Retrospective analyses of pooled data from CREST I and CREST II trials for treatment of cocaine dependence. Addiction 2005, 100(Suppl 1):91-101.
6. Karila L., Gorelick D., Weinstein A., et al. New treatments for cocaine dependence: a focused review. Int J Neuropsychopharmacol 2008, 11(3):425-438.
7. Cami J., Farre M. Drug addiction. N Engl J Med 2003, 349(10):975-986.
8. White F.J., Kalivas P.W. Neuroadaptations involved in amphetamine and cocaine addiction. Drug Alcohol Depend 1998, 51(1-2):141-153.
9. Amato L., Davoli M., Perucci C.A., et al. An overview of systematic reviews of the effectiveness of opiate maintenance therapies: available evidence to inform clinical practice and research. J Subst Abuse Treat 2005, 28(4):321-329.
10. Berrettini W.H., Lerman C.E. Pharmacotherapy and pharmacogenetics of nicotine dependence. Am J Psychiatry 2005, 162(8):1441-1451.
11. Ledford C.C., Fuchs R.A., See R.E. Potentiated reinstatement of cocaine-seeking behavior following D-amphetamine infusion into the basolateral amygdala. Neuropsychopharmacology 2003, 28(10):1721-1729.
12. Chiodo K.A., Lack C.M., Roberts D.C. Cocaine self-administration reinforced on a progressive ratio schedule decreases with continuous D-amphetamine treatment in rats. Psychopharmacology (Berl) 2008, 200(4):465-473.
13. Foltin R.W., Evans S.M. The effects of d-amphetamine on intake of food and a sweet fluid containing cocaine. Pharmacol Biochem Behav 1999, 62(3):457-464.
14. Negus S.S., Mello N.K. Effects of chronic d-amphetamine treatment on cocaine- and food-maintained responding under a progressive-ratio schedule in rhesus monkeys. Psychopharmacology (Berl) 2003, 167(3):324-332.
15. Negus S.S., Mello N.K. Effects of chronic d-amphetamine treatment on cocaine- and food-maintained responding under a second-order schedule in rhesus monkeys. Drug Alcohol Depend 2003, 70(1):39-52.
16. Czoty P.W., Martelle J.L., Nader M.A. Effects of chronic d-amphetamine administration on the reinforcing strength of cocaine in rhesus monkeys. Psychopharmacology (Berl) 2010, 209(4):375-382.
17. Grabowski J., Roache J.D., Schmitz J.M., et al. Replacement medication for cocaine dependence: methylphenidate. J Clin Psychopharmacol 1997, 17(6):485-488.
18. Roache J.D., Grabowski J., Schmitz J.M., et al. Laboratory measures of methylphenidate effects in cocaine-dependent patients receiving treatment. J Clin Psychopharmacol 2000, 20(1):61-68.
19. Rush C.R., Stoops W.W., Hays L.R. Cocaine effects during D-amphetamine maintenance: a human laboratory analysis of safety, tolerability and efficacy. Drug Alcohol Depend 2009, 99(1-3):261-271.
20. Rush C.R., Stoops W.W., Sevak R.J., et al. Cocaine choice in humans during D-amphetamine maintenance. J Clin Psychopharmacol 2010, 30(2):152-159.
21. Fredericks E.M., Kollins S.H. Assessing methylphenidate preference in ADHD patients using a choice procedure. Psychopharmacology (Berl) 2004, 175(4):391-398.
22. Collins S.L., Levin F.R., Foltin R.W., et al. Response to cocaine, alone and in combination with methylphenidate, in cocaine abusers with ADHD. Drug Alcohol Depend 2006, 82(2):158-167.
23. Li C.S., Morgan P.T., Matuskey D., et al. Biological markers of the effects of intravenous methylphenidate on improving inhibitory control in cocaine-dependent patients. Proc Natl Acad Sci U S A 2010, 107(32):14455-14459.
24. Goldstein R.Z., Woicik P.A., Maloney T., et al. Oral methylphenidate normalizes cingulate activity in cocaine addiction during a salient cognitive task. Proc Natl Acad Sci U S A 2010, 107(38):16667-16672.
25. Volkow N.D., Wang G.J., Tomasi D., et al. Methylphenidate attenuates limbic brain inhibition after cocaine-cues exposure in cocaine abusers. PLoS One 2010, 5(7):e11509.
26. Martinez D., Carpenter K.M., Liu F., et al. Imaging dopamine transmission in cocaine dependence: link between neurochemistry and response to treatment. Am J Psychiatry 2011, 168:634-641.
27. Fleckenstein A.E., Volz T.J., Riddle E.L., et al. New insights into the mechanism of action of amphetamines. Annu Rev Pharmacol Toxicol 2007, 47:681-698.
28. Ermer J.C., Adeyi B.A., Pucci M.L. Pharmacokinetic variability of long-acting stimulants in the treatment of children and adults with attention-deficit hyperactivity disorder. CNS Drugs 2010, 24(12):1009-1025.
29. Grabowski J., Rhoades H., Schmitz J., et al. Dextroamphetamine for cocaine-dependence treatment: a double-blind randomized clinical trial. J Clin Psychopharmacol 2001, 21(5):522-526.
30. Grabowski J., Rhoades H., Stotts A., et al. Agonist-like or antagonist-like treatment for cocaine dependence with methadone for heroin dependence: two double-blind randomized clinical trials. Neuropsychopharmacology 2004, 29(5):969-981.
31. Shearer J., Wodak A., van Beek I., et al. Pilot randomized double blind placebo-controlled study of dexamphetamine for cocaine dependence. Addiction 2003, 98(8):1137-1141.
32. Mooney M.E., Herin D.V., Schmitz J.M., et al. Effects of oral methamphetamine on cocaine use: a randomized, double-blind, placebo-controlled trial. Drug Alcohol Depend 2009, 101(1-2):34-41.
33. Margolin A., Avants S.K., Kosten T.R. Mazindol for relapse prevention to cocaine abuse in methadone-maintained patients. Am J Drug Alcohol Abuse 1995, 21(4):469-481.
34. Stine S.M., Krystal J.H., Kosten T.R., et al. Mazindol treatment for cocaine dependence. Drug Alcohol Depend 1995, 39(3):245-252.
35. Dackis C.A., Kampman K.M., Lynch K.G., et al. A double-blind, placebo-controlled trial of modafinil for cocaine dependence. Neuropsychopharmacology 2005, 30(1):205-211.
36. Anderson A.L., Reid M.S., Li S.H., et al. Modafinil for the treatment of cocaine dependence. Drug Alcohol Depend 2009, 104(1-2):133-139.
37. Brodie J.D., Case B.G., Figueroa E., et al. Randomized, double-blind, placebo-controlled trial of vigabatrin for the treatment of cocaine dependence in Mexican parolees. Am J Psychiatry 2009, 166(11):1269-1277.
38. Mooney M.E., Schmitz J.M., Moeller F.G., et al. Safety, tolerability and efficacy of levodopa-carbidopa treatment for cocaine dependence: two double-blind, randomized, clinical trials. Drug Alcohol Depend 2007, 88(2-3):214-223.
39. Leonard B.E., McCartan D., White J., et al. Methylphenidate: a review of its neuropharmacological, neuropsychological and adverse clinical effects. Hum Psychopharmacol 2004, 19(3):151-180.
40. Winhusen T., Somoza E., Singal B.M., et al. Methylphenidate and cocaine: a placebo-controlled drug interaction study. Pharmacol Biochem Behav 2006, 85(1):29-38.
41. Schubiner H., Saules K.K., Arfken C.L., et al. Double-blind placebo-controlled trial of methylphenidate in the treatment of adult ADHD patients with comorbid cocaine dependence. Exp Clin Psychopharmacol 2002, 10(3):286-294.
42. Levin F.R., Evans S.M., Brooks D.J., et al. Treatment of cocaine dependent treatment seekers with adult ADHD: double-blind comparison of methylphenidate and placebo. Drug Alcohol Depend 2007, 87(1):20-29.
43. Minzenberg M.J., Carter C.S. Modafinil: a review of neurochemical actions and effects on cognition. Neuropsychopharmacology 2008, 33(7):1477-1502.
44. Dackis C.A., Lynch K.G., Yu E., et al. Modafinil and cocaine: a double-blind, placebo-controlled drug interaction study. Drug Alcohol Depend 2003, 70(1):29-37.
45. Foley K.F., DeSanty K.P., Kast R.E. Bupropion: pharmacology and therapeutic applications. Expert Rev Neurother 2006, 6(9):1249-1265.
46. Margolin A., Kosten T.R., Avants S.K., et al. A multicenter trial of bupropion for cocaine dependence in methadone-maintained patients. Drug Alcohol Depend 1995, 40(2):125-131.
47. Shoptaw S., Heinzerling K.G., Rotheram-Fuller E., et al. Bupropion hydrochloride versus placebo, in combination with cognitive behavioral therapy, for the treatment of cocaine abuse/dependence. J Addict Dis 2008, 27(1):13-23.
48. Elkashef A., Fudala P.J., Gorgon L., et al. Double-blind, placebo-controlled trial of selegiline transdermal system (STS) for the treatment of cocaine dependence. Drug Alcohol Depend 2006, 85(3):191-197.
49. Schmitz J.M., Mooney M.E., Moeller F.G., et al. Levodopa pharmacotherapy for cocaine dependence: choosing the optimal behavioral therapy platform. Drug Alcohol Depend 2008, 94(1-3):142-150.
50. Schmitz J.M., Lindsay J.A., Stotts A.L., et al. Contingency management and levodopa-carbidopa for cocaine treatment: a comparison of three behavioral targets. Exp Clin Psychopharmacol 2010, 18(3):238-244.
51. Poling J., Oliveto A., Petry N., et al. Six-month trial of bupropion with contingency management for cocaine dependence in a methadone-maintained population. Arch Gen Psychiatry 2006, 63(2):219-228.
52. Moeller F.G., Schmitz J.M., Steinberg J.L., et al. Citalopram combined with behavioral therapy reduces cocaine use: a double-blind, placebo-controlled trial. Am J Drug Alcohol Abuse 2007, 33(3):367-378.
53. Kosten T., Oliveto A., Feingold A., et al. Desipramine and contingency management for cocaine and opiate dependence in buprenorphine maintained patients. Drug Alcohol Depend 2003, 70(3):315-325.
54. Schubiner H., Tzelepis A., Milberger S., et al. Prevalence of attention-deficit/hyperactivity disorder and conduct disorder among substance abusers. J Clin Psychiatry 2000, 61(4):244-251.
55. Levin F.R., Evans S.M., Kleber H.D. Prevalence of adult attention-deficit hyperactivity disorder among cocaine abusers seeking treatment. Drug Alcohol Depend 1998, 52(1):15-25.
56. Kessler R.C., Adler L., Barkley R., et al. The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. Am J Psychiatry 2006, 163(4):716-723.
57. Spencer T., Biederman J., Wilens T., et al. Efficacy of a mixed amphetamine salts compound in adults with attention-deficit/hyperactivity disorder. Arch Gen Psychiatry 2001, 58(8):775-782.
58. Faraone S.V., Spencer T., Aleardi M., et al. Meta-analysis of the efficacy of methylphenidate for treating adult attention-deficit/hyperactivity disorder. J Clin Psychopharmacol 2004, 24(1):24-29.
59. Wilens T.E., Faraone S.V., Biederman J., et al. Does stimulant therapy of attention-deficit/hyperactivity disorder beget later substance abuse?. A meta-analytic review of the literature. Pediatrics 2003, 111(1):179-185.
60. Volkow N.D., Swanson J.M. Variables that affect the clinical use and abuse of methylphenidate in the treatment of ADHD. Am J Psychiatry 2003, 160(11):1909-1918.
61. Wilens T.E., Adler L.A., Adams J., et al. Misuse and diversion of stimulants prescribed for ADHD: a systematic review of the literature. J Am Acad Child Adolesc Psychiatry 2008, 47(1):21-31.
62. Kollins S.H., MacDonald E.K., Rush C.R. Assessing the abuse potential of methylphenidate in nonhuman and human subjects: a review. Pharmacol Biochem Behav 2001, 68(3):611-627.
63. Kollins S.H. Abuse liability of medications used to treat attention-deficit/hyperactivity disorder (ADHD). Am J Addict 2007, 16(Suppl 1):35-42. [quiz: 43-4].
64. Rush C.R., Essman W.D., Simpson C.A., et al. Reinforcing and subject-rated effects of methylphenidate and d-amphetamine in non-drug-abusing humans. J Clin Psychopharmacol 2001, 21(3):273-286.
65. Stoops W.W., Glaser P.E., Fillmore M.T., et al. Reinforcing, subject-rated, performance and physiological effects of methylphenidate and d-amphetamine in stimulant abusing humans. J Psychopharmacol 2004, 18(4):534-543.
66. Kollins S.H., Rush C.R., Pazzaglia P.J., et al. Comparison of acute behavioral effects of sustained-release and immediate-release methylphenidate. Exp Clin Psychopharmacol 1998, 6(4):367-374.